Search research articles
Contact Us
Filters
Showing results (331-340 of 499) with videos related to
Page
of 50
Sort By:
Cancer Research Communications
|
April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
James J Harding, Ralf Hofheinz, Elena Élez, et al.
The Lancet. Oncology
|
February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 12, 2021
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, et al.
Journal of the National Cancer Institute
|
October 11, 2013
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis
Koji Oba, Xavier Paoletti, Steven Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2023
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer
Eric Van Cutsem, Julien Taieb, Rona Yaeger, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
August 1, 2019
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 24, 2017
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
Akira Sawaki, Yasuhide Yamada, Kensei Yamaguchi, et al.
The Oncologist
|
October 12, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2014
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, et al.
The Lancet. Oncology
|
June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
Julien Taieb, Josep Tabernero, Enrico Mini, et al.
Page
of 50
Search research articles
Search
Showing results (331-340 of 499) with videos related to
Sort By:
Page
of 50
Cancer Research Communications
|
April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
James J Harding, Ralf Hofheinz, Elena Élez, et al.
The Lancet. Oncology
|
February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 12, 2021
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, et al.
Journal of the National Cancer Institute
|
October 11, 2013
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis
Koji Oba, Xavier Paoletti, Steven Alberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2023
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer
Eric Van Cutsem, Julien Taieb, Rona Yaeger, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
August 1, 2019
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 24, 2017
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
Akira Sawaki, Yasuhide Yamada, Kensei Yamaguchi, et al.
The Oncologist
|
October 12, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2014
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, et al.
The Lancet. Oncology
|
June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
Julien Taieb, Josep Tabernero, Enrico Mini, et al.
Page
of 50